LCLucy Culliford

Lucy Culliford

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lucy Culliford has a total of 376 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial

    by Rosie Harris, Russell Thirard, Claire McBrien, Alexander Middleditch, David Chadwick, John Jackson, Ed Moran, James Perry, Ruth A Payne, Anna L Goodman, et al.


  • Open Access

    Challenges of delivering a lifestyle intervention before surgery in multiple surgical specialties in the NHS: experience from the INSPIRE trial

    by Emma Bridgeman, Chloe Beard, Katherine Joyce, Denny Levett, Dawn Phillips, Maria Pufulete, Lucy Culliford

    This paper describes the challenges of undertaking a trial of a pre-operative lifestyle intervention in multiple surgical specialties, the INSPIRE trial, and additional challenges of doing so during the COVID-19 pandemic. The INSPIRE trial was a randomised controlled trial to test if inspiratory muscle training could reduce the incidence of postoperative pulmonary complications in patients undergoing cardiac, thoracic and abdominal elective surgery. We present the challenges of trial conduct alongside the adaptations introduced to mitigate the impact of those challenges. The INSPIRE trial was halted by the funder at the end of the internal pilot phase. We were therefore unable to assess the effect of some of the adaptations, and there were further adaptations we were unable to make. We are using our experience to make recommendations for future similar trials.

  • Open Access

    The effects of a theory-informed cover letter on follow-up response rates in an adult cardiac surgery study: a randomised study within a trial (SWAT 24).

    by Rachel Maishman, Katherine Joyce, Terrie Walker-Smith, Helena Smart, Lucy Culliford

    Background Clinical studies can experience major loss to follow-up and reduced response rates to participant reported outcomes such as quality of life questionnaires, which can lead to a lack of statistical power for the analysis of these outcomes. A number of studies have been embedded within trials to investigate interventions to improve retention. Methods A Study Within a Trial (SWAT) was integrated into the Outcome Monitoring After Cardiac Surgery (OMACS) study, a large observational cardiac surgery study, to investigate whether the use of a theory-informed cover letter with 12-month follow-up questionnaires could improve study retention. OMACS study participants receiving 12-month follow-up questionnaires by post were randomised in a 1:1 ratio to receive either a standard cover letter or a theory informed cover letter with their questionnaires. Study retention was assessed by the proportion of participants who returned 12-month follow-up questionnaires. Results Questionnaire return rates were similar between the two groups (67.4% with the standard cover letter compared to 68.5% with the theory-informed cover letter, odds ratio 1.05, 95% confidence interval (CI) [0.85 to 1.31]). The results of the OMACS SWAT were consistent with the previously reported meta-analysis (MA) by Gillies et al. , with a revised risk difference of 3% (95% CI -1% to 6%) when including OMACS in the MA. Conclusions There is insufficient evidence to support the use of a theory-informed cover letter to increase study retention. We would recommend study teams explore alternative strategies for improving retention where needed. Trial registration: ISRCTN90204321, registered on 21/01/2015, https://doi.org/10.1186/ISRCTN90204321.

  • Open Access

    Microfracture with or without collagen scaffold insertion for adults with chondral or osteochondral defects of the knee: the SISMIC RCT and its challenges during and after the COVID-19 pandemic

    by Michael R Whitehouse, Nicholas Howells, Lucy Dabner, Russell Thirard, Lucy Culliford, Elsa Marques, Petra Baji, Andrew Judge, Ashley W Blom, Amanda Burston, et al.

    Background: Around 10,000 symptomatic knee articular cartilage injuries requiring repair occur annually in the United Kingdom, mostly in people under 35 years of age. Microfracture surgery aims to restore cartilage. Adding microstructural scaffolds made of collagen may further improve outcomes. Objectives: To evaluate the clinical and cost-effectiveness of microstructural scaffold in patients undergoing microfracture for a symptomatic chondral or osteochondral defect of the knee. Design: Multicentre, parallel two-group, superiority randomised controlled trial with blinding of participants, research staff and clinical care teams not involved in the surgery. Setting: National Health Service hospitals offering arthroscopic chondral surgery. Participants: Adults aged 18 years or older with symptomatic chondral or osteochondral defects of the knee on the medial or lateral femoral condyles, trochlea or patella and a chondral or osteochondral lesion measuring no more than 4 cm 2 . Exclusions were: unstable ligamentous injuries or meniscal tears that would not be treated; a knee with defects on the tibial chondral surface, < 50% native meniscal volume or requiring realignment surgery/osteotomy; and a lesion previously treated with microfracture. Interventions: Lesions were debrided, and microfracture was performed on the exposed subchondral bone. Intervention: microfracture of the chondral or osteochondral lesion with insertion of a bilayer collagen matrix microstructural scaffold, fixed with stiches or fibrin glue. Comparator: microfracture alone. Postoperative physiotherapy was standardised. Participants were randomised 1 : 1 between intervention and control. Main outcome measures: Primary outcome was the Knee Injury and Osteoarthritis Outcome Score at 24 months post randomisation. Secondary outcomes included International Knee Documentation Committee knee evaluation score; Tegner-Lysholm activity grading scale; EuroQol-5 Dimensions, five-level version; Work Productivity and Activity Impairment; complications and resource use measured at 3, 6, 12 and 24 months. Results: Twenty-two patients were screened across 8 sites, 20 of whom were eligible on screening. Of the 20 patients considered initially eligible, 2 patients were not interested and 1 opted for chondroplasty; the remaining 17 all consented to participate. Between November 2021 and October 2022, 10 participants were randomised, 5 to microfracture and 5 to microfracture with scaffold. Three patients failed the final in-surgery eligibility check (lesions had healed), one decided not to have surgery and three were still waiting when the study was closed. The median age was 38 years, and four participants were female. Most participants (seven) had damage to the lateral femoral condyle, and six had a medial and/or lateral meniscal tear. All participants received the allocated treatment and are included in the reported results. When a scaffold was used, the surgery took on average 10 minutes longer. There were three serious adverse events, knee pain and swelling in one participant, and a suspected anaphylactic reaction in another. Limitations: The SISMIC randomised controlled trial did not progress beyond the internal pilot phase due to insufficient recruitment. The target number of sites were opened, but recruitment was only 42% of the target 24 participants randomised. Insufficient data were collected to answer the research question. Conclusions: The SISMIC randomised controlled trial was severely impacted by the COVID-19 pandemic, the limited resources available at sites and the reduced elective orthopaedic surgical activity. Future work: To reflect contemporary practice, we recommend that a future trial evaluates three treatments: chondroplasty, chondroplasty with a microstructural scaffold and autologous chondrocyte implantation. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR127849.

  • Open Access

    Gabapentin for Pain Management after Major Surgery: A Placebo-controlled, Double-blinded, Randomized Clinical Trial (the GAP Study)

    by Sarah Baos, Mandy Msc Lui, Terrie Bsc Walker-Smith, Maria Pufulete, David Frcs Messenger, Reyad Frcs Abbadi, Tim Fcrs Batchelor, Gianluca Frcs Casali, Mark Md Frca Edwards, Nick Frca Goddard, et al.

    Background: Gabapentin is an anticonvulsant medication with approval for use in neuropathic pain and epileptic disorders. It is frequently added to multimodal analgesic regimens during and after surgery to reduce opioid use while controlling pain effectively. There is little evidence to show its effectiveness in major surgery. Methods: In this multicenter, double-blinded randomized controlled trial, adults undergoing major cardiac, thoracic, or abdominal surgery were randomized to receive either gabapentin (600 mg before surgery, 300 mg twice daily for 2 days after surgery) or placebo. The primary outcome was length of hospital stay. Secondary outcomes included acute and chronic pain, total opioid use, adverse health events, and health-related quality of life. Patients were followed up daily in-hospital until discharge and then at 4 weeks and 4 months after surgery. Results: A total of 1,196 participants were randomized (500 underwent cardiac, 346 thoracic, and 350 abdominal surgery); 596 were allocated to placebo, and 600 were allocated to gabapentin. Median length of hospital stay was similar in the two groups (gabapentin, 5.94 [interquartile range (IQR), 4.08 to 8.04] days; placebo, 6.15 [IQR, 4.22 to 8.97] days; hazard ratio, 1.07; 95% CI, 0.95 to 1.20; P = 0.26). Overall, 384 participants experienced one or more serious adverse events (gabapentin, 189 of 596 [31.7%]; placebo, 195 of 599 [32.6%]), with some variation across surgical specialties. Conclusions: Among patients undergoing major cardiac, thoracic, and abdominal surgery, adding gabapentin to multimodal analgesic regimes did not alter the length of hospital stay or the number of serious adverse events.


  • Open Access

    Cohort profile: Outcome Monitoring After Cardiac Surgery (OMACS) – a prospective UK cohort study of cardiac surgery patients at the Bristol Heart Institute

    by Katherine Joyce, Rachel Maishman, Terrie Walker-Smith, Helena Smartt, Emma Hopkins, Penny Lambert, Gianni Angelini, Chris A Rogers, Barnaby Reeves, Rachel Brierley, et al.

    Purpose: The Outcome Monitoring After Cardiac Surgery (OMACS) cohort study was set-up with the aim of establishing a rich source of biological samples and health status data from patients who undergo cardiac surgery. The objectives were to use these data to inform the design of new clinical studies and to provide samples and data to answer research questions. Participants: Recruitment began on 23 May 2016 and ended 31 May 2022. Adult patients undergoing cardiac surgery at University Hospitals Bristol and Weston NHS Foundation Trust were screened and approached for consent. Participants could optionally consent to provide biological samples (urine, blood and waste tissue) in addition to data. A total of 4068 patients consented to participate in the study with 2027 consenting to donate samples. Participants were sent quality-of-life follow-up questionnaires at 3 and 12 months after surgery. The clinical data were collected from hospital records/databases. Findings to date: The OMACS population appears to be representative of the wider cardiac surgery population with similar preoperative demography to those reported on the UK surgery population. To date, eight studies have been carried out by research teams using data from a total of 1165 OMACS participants. Two Studies Within A Trial have been performed by the OMACS study team. The format of the study patient information leaflet was not significantly associated with an increased recruitment rate, and an alternative theory-informed cover letter included with the 12-month follow-up questionnaires was not associated with an increase in questionnaire completion. Additional exploratory research carried out within the OMACS study has been presented at international conferences. Future plans: The OMACS study is now closed. The cohort’s data and samples will be available to share with researchers, providing an opportunity to answer a variety of research questions (eg, evaluating predictors of adverse outcomes after cardiac surgery such as biomarkers, surgical methods and pre-existing conditions). The data and samples will be available for sharing in a linked anonymised format. Trial registration number: ISRCTN90204321 (date assigned: 21 January 2015).


  • Open Access

    Prehabilitation for frail patients undergoing hip and knee replacement in the UK: Joint PREP feasibility study for a randomised controlled trial

    by Tanzeela Khalid, Yoav Ben-Shlomo, Wendy Bertram, Lucy Culliford, Emily J Henderson, Marcus Jepson, Emma Johnson, Alex Mitchell, Shea Palmer, Jonathan Thomas Evans, et al.

    Objective To determine the feasibility of conducting a randomised controlled trial (RCT) to evaluate a prehabilitation programme for frail patients undergoing total hip replacement (THR) or total knee replacement (TKR). Design Randomised feasibility study with embedded qualitative work. Setting Three National Health Service hospitals. Participants Adults aged ≥65 years, frail and scheduled for primary THR or TKR. Intervention Appointment with a physiotherapist to individualise a home-based exercise programme. Participants were encouraged to do the home exercises daily for 12 weeks pre-operative and were provided with a daily protein supplement. Participants were supported by six telephone calls over the 12-week intervention period. Outcome measures Eligibility and recruitment rates, intervention adherence, data completion rates of patient-reported outcome measures, retention rates and acceptability of the trial and intervention. Qualitative interviews were conducted with participants and non-participants and analysed using thematic analysis. Results Between December 2022 and August 2023, 411 patients were sent a screening pack. Of the 168 patients who returned a screening questionnaire, 79 were eligible and consented to participate, and 64 were randomised. Of the 33 participants randomised to the intervention, 26 attended the intervention appointment. Eighteen participants (69%) received all six intervention follow-up telephone calls. Nineteen participants (73%) completed an intervention adherence log; 13 (68%) adhered to the exercise programme and 11 (58%) adhered to the protein supplementation. The overall retention rate was 86% (55/64 overall) at 12 weeks. The 12-week follow-up questionnaire was returned by 46 of the 55 participants (84%) who were sent a questionnaire. Interviews with 19 patients found that the trial processes and intervention were generally acceptable, but areas of potential improvements were identified. Conclusions This study demonstrated that a larger study is possible and has identified improvements to optimise the design of an RCT. Trial registration number ISRCTN11121506.


  • Open Access

    Bezafibrate as treatment in males for Barth syndrome: CARDIOMAN, a double-blind, placebo-controlled crossover RCT

    by Guido Pieles, Colin Steward, Lucy Dabner, Laura Collet, Lucy Culliford, Karen Sheehan, Lucy Ellis, Michaela Damin, Eva Sammut, Nuno Duarte, et al.

    Background: Barth syndrome is a rare, life-threatening X-linked recessive mitochondrial disorder of lipid metabolism primarily affecting males. Previous research suggests that bezafibrate may ameliorate cellular lipid abnormalities and reduce cardiac dysfunction in an animal model. Objectives: Estimate the effect of bezafibrate on clinical, biochemical, and quality-of-life outcomes. Investigate whether within-participant clinical changes parallel in vitro changes in cardiolipin ratio/profile and mitochondrial morphology when each participant’s cells are cultured with bezafibrate. Investigate as for objective 2, culturing each participant’s cells with resveratrol. Describe the most feasible methods and standardised outcome measures to optimise the conduct of future trials and evaluations in Barth syndrome. Describe features of the research infrastructure which optimised recruitment, retention and communication with families and people with Barth syndrome. Describe the perceptions of participants and their families about the research and any important potential barriers to participation. Design: Randomised, placebo-controlled, crossover trial of bezafibrate versus placebo. Setting: NHS hospital providing UK-wide Barth Syndrome Service. Participants: Males aged ≥ 6 years with a confirmed diagnosis of Barth syndrome with stable cardiac status, able to swallow tablets of bezafibrate/placebo. Exclusions were: hypersensitivity or allergy to bezafibrate or any component of bezafibrate; hepatic, liver or renal dysfunction; gallbladder disease; or recent deterioration in general health. Interventions: Fifteen weeks of bezafibrate in one period and placebo in a second period, or vice versa (randomly allocated), with at least a 1-month washout between periods. Main outcome measures: The primary outcome was peak VO2; secondary outcomes were cardiac function rest and exercise echocardiography and magnetic resonance imaging, cardiolipin ratio, quality of life, dynamic skeletal muscle P-magnetic resonance spectroscopy, mitochondrial studies and neutrophil counts, and adverse events. Outcomes were measured at baseline and the end of each period. Results: Eleven males were studied; all attended all three assessments. There was no difference in peak VO2 between periods (0.66 ml/kg/min lower with bezafibrate than placebo, 95% confidence interval 2.34 to 1.03; p = 0.43). There was a trend towards a higher left ventricular ejection fraction with bezafibrate when measured by echocardiography but not magnetic resonance imaging, and better echocardiography-derived rest longitudinal and circumferential strain with bezafibrate. There was no difference in quality of life or cardiolipin ratio between periods. Skeletal muscle 31P magnetic resonance spectroscopy was performed cross-sectionally and showed a trend to higher Tau and lower Qmax indices in the bazafibrate group. Two participants had serious, expected adverse reactions when taking bezafibrate; otherwise, bezafibrate was well tolerated. Limitations: The sample size was very small; the bezafibrate dose may have been too low or 15 weeks too short to observe an effect; measurements of mitochondrial content and membrane potential were highly variable; P-magnetic resonance spectroscopy was available only at the final assessment. Conclusions: This study did not show significant improvement in the primary and secondary outcomes with bezafibrate treatment. Future work: Elamipretide, studied in a small crossover trial in the USA, is another potential intervention which may be worth evaluating in an international study. Trial registration: This trial is registered as ISRCTN58006579. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 12/205/56) and is published in full in Efficacy and Mechanism Evaluation; Vol. 11, No. 13. See the NIHR Funding and Awards website for further award information.


  • Open Access

    Effectiveness and cost-effectiveness of radiofrequency denervation versus placebo for chronic and moderate to severe low back pain: study protocol for the RADICAL randomised controlled trial

    by Kate E Ashton, Cathy Price, Leah Fleming, Ashley W Blom, Lucy Culliford, Rebecca Nicole Evans, Nadine E Foster, William Hollingworth, Catherine Jameson, Nouf Jeynes, et al.

    Introduction Low back pain (LBP) is the leading global cause of disability. Patients with moderate to severe LBP who respond positively to a diagnostic medial nerve branch block can be offered radiofrequency denervation (RFD). However, high-quality evidence on the effectiveness of RFD is lacking. Methods and analysis RADICAL (RADIofrequenCy denervAtion for Low back pain) is a double-blind, parallel-group, superiority randomised controlled trial. A total of 250 adults listed for RFD will be recruited from approximately 20 National Health Service (NHS) pain and spinal clinics. Recruitment processes will be optimised through qualitative research during a 12-month internal pilot phase. Participants will be randomised in theatre using a 1:1 allocation ratio to RFD or placebo. RFD technique will follow best practice guidelines developed for the trial. Placebo RFD will follow the same protocol, but the electrode tip temperature will not be raised. Participants who do not experience a clinically meaningful improvement in pain 3 months after randomisation will be offered the alternative intervention to the one provided at the outset without disclosing the original allocation. The primary clinical outcome will be pain severity, measured using a pain Numeric Rating Scale, at 3 months after randomisation. Secondary outcomes will be assessed up to 2 years after randomisation and include disability, health-related quality of life, psychological distress, time to pain recovery, satisfaction, adverse events, work outcomes and healthcare utilisation. The primary statistical analyses will be by intention to treat and will follow a prespecified analysis plan. The primary economic evaluation will take an NHS and social services perspective and estimate the discounted cost per quality-adjusted life-year and incremental net benefit of RFD over the 2-year follow-up period. Ethics and dissemination Ethics approval was obtained from the London—Fulham Research Ethics Committee (21/LO/0471). Results will be disseminated in open-access publications and plain language summaries. Trial registration number ISRCTN16473239.


  • Open Access

    The clinical and cost-effectiveness of elective primary total knee replacement with PAtellar Resurfacing compared to selective patellar resurfacing: a pragmatic multicentre randomized controlled Trial (PART)

    by Adam Boon, Elizabeth Barnett, Lucy Culliford, Rebecca Evans, Jessica Frost, Zastra Hansen-Kaku, William Hollingworth, Emma Johnson, Andrew Judge, Elsa M. R. Marques, et al.

    The clinical and cost-effectiveness of elective primary total knee replacement with PAtellar Resurfacing compared to selective patellar resurfacing: a pragmatic multicentre randomized controlled Trial (PART)